Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102.
Philips, G; Halabi, S; Sanford, B; Bajorin, D; Small, E
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Conference Start Date
Conference End Date